{
    "clinical_study": {
        "@rank": "4676", 
        "arm_group": [
            {
                "arm_group_label": "Zevalin", 
                "arm_group_type": "Experimental", 
                "description": "90Y-Ibritumomab tiuxetan will be administered 8 to 12 weeks after the last chemotherapy infusion. Each patient randomized to this treatment group will receive a therapeutic dose of 14.8 MBq/kg (0.4 mCi/kg of total body weight) of 90Y ibritumomab tiuxetan (maximum 1,184 MBq or 32 mCi). Patients with a pre-treatment platelet count between 100 and 149 x109/L will receive 0.3 mCi/Kg 90Y-ibritumomab tiuxetan.The 90Y ibritumomab tiuxetan regimen is as follows: Day 1 rituximab (250 mg/m2); Day 7,8, or 9 rituximab (250 mg/m2) followed by 90Y ibritumomab tiuxetan within 4 hours of the end of the rituximab infusion."
            }, 
            {
                "arm_group_label": "Rituximab", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will receive 375 mg/m2 of rituximab, administered by I.V. infusion every 8 weeks, starting 8 to 12 weeks after the last R-chemotherapy cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of consolidation treatment Zevalin\u00ae\n      versus maintenance treatment with Rituxan\u00ae on progression-free survival (PFS) following\n      response induction with chemotherapy plus rituximab in previously untreated patients with\n      follicular lymphoma."
        }, 
        "brief_title": "Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Follicular Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Follicular"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, multicenter and randomized study. Patients will be registered after\n      response induction (PR/CR) to R-chemotherapy. Patients achieving either a PR or CR following\n      R-chemotherapy will be eligible for randomization to either consolidation with\n      90Y-ibritumumab tiuxetan followed by observation for 24 months, or rituximab maintenance for\n      24 months. After the observation/maintenance period, patients will be followed for 5 years.\n\n      This study is designed to be similar to the ZAR2007 study (EUDRACT No. 2007-006601-25)\n      carried out by PETHEMA in Spain. It is expected that Spanish centers will contribute up to\n      230 patients; centers in the US and elsewhere will contribute the remaining 254 patients.\n      The same randomization procedure will be used in both studies. The total sample size for the\n      combined studies will be 484 randomized patients. Assuming that PFS will follow an\n      exponential distribution with a constant hazard rate, with a 36 months uniform accrual\n      period and an additional follow-up time of 60 months after the last patient is randomized,\n      242 patients per arm (484 total) will be necessary to observe 131 PFS events in the combined\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 to 75 years of age\n\n          -  Previously untreated with histologically confirmed grade 1, 2 or 3a CD20-positive\n             follicular lymphoma, with any of the GELF (Groupe d'Etude de Lymphomes Folliculaires)\n             treatment criteria prior to induction.\n\n          -  Achieved a response to induction treatment with either R-CHOP (6 cycles of R-CHOP21\n             or R-CHOP14), R-CVP (6 cycles), or R-B (4 to 6 cycles).\n\n          -  Must have completed all doses of the induction treatment, except for the\n             modifications allowed in the protocol.\n\n        Exclusion Criteria:\n\n          -  Transformation to high grade lymphoma (secondary to \"low grade\" FL)\n\n          -  Grade 3b follicular lymphoma\n\n          -  Primary follicular lymphoma of the skin or gastrointestinal tract\n\n          -  Previous treatment of follicular lymphoma\n\n          -  Altered renal and hepatic function\n\n          -  Known HIV infection and/or active HBV and/or HCV infection\n\n          -  Serious co-morbid conditions (for example, ongoing infection, uncontrolled diabetes\n             mellitus, gastric ulcers, active autoimmune disease).\n\n          -  Life expectancy < 6\n\n          -  Must have:\n\n               -  Platelet count \u2265 100x109/L\n\n               -  Bone marrow infiltration <25%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662102", 
            "org_study_id": "SPI-ZEV-12-302"
        }, 
        "intervention": [
            {
                "arm_group_label": "Zevalin", 
                "description": "Group A: Response consolidation with a single dose of 90Y-ibritumomab tiuxetan (Zevalin\u00ae) 0.4 mCi/Kg - Maximum dose: 32 mCi given with 2 doses of rituximab followed by observation for 24 months;", 
                "intervention_name": "Zevalin", 
                "intervention_type": "Drug", 
                "other_name": "90Y-ibritumomab tiuxetan (Zevalin)"
            }, 
            {
                "arm_group_label": "Rituximab", 
                "description": "Group B: Response maintenance with 375 mg/m2 of rituximab every 8 weeks for 24 months (12 infusions)", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "Rituxan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rituximab", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sun City", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85351"
                    }, 
                    "name": "21st Century Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30607"
                    }, 
                    "name": "Northeast Georgia Cancer Care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Niles", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60714"
                    }, 
                    "name": "Illinois Cancer Specialists"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis Park", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55426"
                    }, 
                    "name": "Park Nicollet Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "West Virginia", 
                        "zip": "25304"
                    }, 
                    "name": "Charleston Area Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin\u00ae Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy", 
        "overall_official": [
            {
                "affiliation": "M.D. Anderson Cancer Center", 
                "last_name": "Fernando Cabanillas, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Mayo Clinic & Foundation", 
                "last_name": "Thomas Witzig, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "21st Century Oncology", 
                "last_name": "Steven E Finkelstein, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Illinois Cancer Specialists - US Oncology", 
                "last_name": "Leonard Klein, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "West Virginia University", 
                "last_name": "Steven Jubelirer, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Northeast Georgia Cancer Care", 
                "last_name": "Petros Nikolinakos, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Progression-free survival (PFS), defined as time from randomization to progression, relapse and/or death from any cause, or need for a new treatment regardless of reason.", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Complete Response (CR) rates post randomization", 
                "measure": "Complete Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "EFS time is defined as the time from randomization to first documented progression, death from any cause, or introduction of a new anti-lymphoma treatment (chemotherapy, radiotherapy or immunotherapy).", 
                "measure": "Event Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "TTP is defined as the time from randomization to the first disease progression.", 
                "measure": "Time to Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "TTNLT is defined as the time from randomization to the first introduction of any new anti lymphoma regimen.", 
                "measure": "Time to Next Anti-Lymphoma Treatment (TTNLT)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "TTNCT is defined as the time from randomization to the first introduction of any new chemotherapy (cytotoxic or radioimmunotherapy). The TTNCT may be the same as the TTNLT. Patients who respond to treatment and patients who are lost to follow-up will be censored at the visit on which the dosing of a new medication was evaluated.", 
                "measure": "Time to Next Chemotherapy (TTNCT)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "OS is defined as the time from randomization to death from any cause. In living patients, survival time will be censored on the last date patients were known to be alive.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "Tumor response will be evaluated according to Cheson criteria at the time of randomization and at the end of the 2-year maintenance/observation, post randomization. ORR is defined as the proportion of patients with a CR or a PR, and will be compared between treatment groups. Patients with no response evaluation (for any reason) will be considered as not evaluable (NE).", 
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "Transformation rate at first progression, defined as the appearance of diffuse areas of large lymphoma cells within a tumor site.", 
                "measure": "Transformation at First Progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "QoL will be assessed through EORTC FACT-G and QLQ-[C]30 questionnaires, and will be compared at each specified time point between treatment arms.", 
                "measure": "Quality of Life (QoL)", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "A cost-effectiveness analysis will be done that compares the efficiency (cost/effectiveness unit) of consolidation treatment with 90Y-ibritumomab tiuxetan compared to maintenance treatment with rituximab. The analysis will be conducted according to a health economic analysis plan independent from this clinical study protocol.", 
                "measure": "Pharmacoeconomics (cost effectiveness analysis)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Spectrum Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spectrum Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013", 
        "why_stopped": "Sponsor decision"
    }
}